GLP-1 Market Key Players Analysis - AstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Market Size, Share & Trends Analysis Report By Type of Molecule (Biologics and Small Molecules), Active Compound Used (Dulaglutide, Liraglutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide and Other Active Compounds), Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist and Short-acting GLP-1 Agonist), Type of Agonist (Single-agonist, Dual-agonist and Tri-agonist), Route of Administration (Oral and Parenteral), Target indication (Alzheimer's Disease, Non-Alcoholic Steatohepatitis, Obesity, Sleep Apnea, Type 2 Diabetes)- Market Outlook And Industry Analysis 2034"

The Global GLP-1 Market is valued at USD 50.0 Billion in 2024, and it is expected to reach USD 141.9 Billion by the year 2034, with a CAGR of 11.1% during the forecast period of 2025-2034..

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2592

Glucagon-like peptide-1 (GLP-1) is an endogenous hormone secreted in the gastrointestinal tract that plays a critical role in the regulation of blood glucose levels and appetite control. GLP-1 receptor agonists are therapeutic agents engineered to activate the GLP-1 receptor, thereby eliciting several clinically beneficial effects. These include the stimulation of insulin secretion from pancreatic beta cells in response to elevated blood glucose, inhibition of glucagon release, delayed gastric emptying, and improved glucose uptake in peripheral tissues. Owing to these mechanisms, GLP-1 receptor agonists have demonstrated substantial efficacy in the management of type 2 diabetes, offering the added advantage of weight reduction-an important consideration for many patients. Additionally, select GLP-1 receptor agonists have received regulatory approval for the treatment of obesity due to their appetite-suppressing and weight-loss-inducing properties.

The GLP-1 receptor agonist market comprises both approved and investigational therapies. Notable examples include short-acting agents such as exenatide and lixisenatide, as well as long-acting formulations like semaglutide, dulaglutide, and liraglutide. Oral formulations, including oral semaglutide (Rybelsus), further broaden treatment options. In addition, next-generation therapies-such as dual and tri-agonists like tirzepatide that target multiple hormonal pathways-are under active investigation. The rising global prevalence of type 2 diabetes and obesity, coupled with the proven efficacy and safety of existing GLP-1 therapies, continues to drive strong market demand. Ongoing innovations and pharmaceutical advancements are expected to further expand the therapeutic landscape, reinforcing the market's growth trajectory in the years ahead.

List of Prominent Players in the GLP-1 Market:
• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Innogen
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The global surge in type 2 diabetes and obesity is a primary catalyst for the growth of the GLP-1 receptor agonist market. According to findings published in the Journal of the American Medical Association, the prevalence of diabetes increased from 3.0% to 4.1%, while obesity rates rose from 32.7% to 40.9% between 2009 and 2020. GLP-1 receptor agonists have demonstrated robust clinical efficacy in reducing blood glucose levels, lowering HbA1c, and supporting meaningful weight loss. Regulatory approvals, such as that of semaglutide (Wegovy) for obesity in addition to diabetes, have broadened the eligible patient population and are significantly accelerating market expansion. Improvements in insurance coverage and affordability are also contributing to increased patient access. Furthermore, innovations in drug delivery-such as oral formulations and once-weekly injectable options-are enhancing treatment convenience and adherence, addressing critical gaps in diabetes and obesity management.

Challenges:
Despite their therapeutic benefits, GLP-1 receptor agonists face several limitations. Patient adherence can be hindered by gastrointestinal side effects, including nausea and vomiting, which may impact long-term usage. While once-weekly injectables offer a more convenient alternative to daily administration, the requirement for subcutaneous injection remains a barrier for some patients. Although oral formulations such as semaglutide have improved accessibility, there is ongoing demand for longer-acting agents with less frequent dosing schedules. Additionally, the high cost of therapy and inconsistent insurance coverage-particularly in low- and middle-income countries-pose significant barriers to market penetration, highlighting the need for more affordable and widely accessible treatment options.

Regional Trends:
The Asia-Pacific (APAC) region is emerging as a high-growth market for GLP-1 receptor agonists, led by countries such as China, India, and Japan. Market expansion in this region is driven by an increasing burden of diabetes and obesity, improvements in healthcare infrastructure, and a large underserved patient population. The rising incidence of metabolic disorders is generating considerable demand for advanced therapeutic solutions. In response, leading pharmaceutical manufacturers are intensifying their focus on the APAC region by investing in innovative GLP-1 therapies and expanding their commercial presence to better meet the region's evolving healthcare needs.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2592

Recent Developments:
• In November 2023, The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's ZepboundTM (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
• In Dec 2021, Shanghai Innogen Pharma successfully completed a $120 million Series A funding round to support its Phase III trial of supaglutide, a GLP-1 agonist targeting diabetes. The funds will also be used to advance several first-in-class programs and establish a clinical trial manufacturing facility.

Segmentation of GLP-1 Market-
By Type of Molecule:
• Biologics
• Small Molecules
By Active Compound Used:
• Dulaglutide
• Liraglutide
• Orforglipron
• Retatrutide
• Semaglutide
• Survodutide
• Tirzepatide
• Other Active Compounds
By Type of GLP-1 Agonist Drugs:
• Long-acting GLP-1 Agonist
• Short-acting GLP-1 Agonist
By Type of Agonist:
• Single agonist
• Dual agonist
• Tri-agonist
By Route of Administration:
• Oral
• Parenteral
By Target Indication:
• Alzheimer's Disease
• Non-Alcoholic Steatohepatitis
• Obesity
• Sleep Apnea
• Type 2 Diabetes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/glp-1-market/2592

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.